Latest Lead News

Argent Minerals has reported outstanding high-grade silver and polymetallic mineralisation from diamond drillhole AKDD208 at its Kempfield project, revealing extensive zones that could significantly boost the resource base.

FSA Group Limited has priced its second asset-backed securities deal, raising $300 million secured by automobile and equipment receivables. The transaction, arranged by National Australia Bank, signals growing momentum in the company's securitisation strategy.

Resimac Group has successfully settled a A$1 billion non-conforming residential mortgage backed securities transaction, marking its second such bond issuance this year. The deal attracted strong domestic and offshore investor interest, reinforcing Resimac’s diversified funding strategy.

Challenger Limited has announced the Dividend Reinvestment Plan (DRP) issue price for its final 2025 dividend at $8.3615 per share, with a modest 2% participation rate leading to the issuance of approximately 266,000 new shares.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Midas Minerals has raised $11.5 million through a strongly supported placement to fund its acquisition and exploration efforts at the Otavi Copper Project in Namibia.

Western Gold Resources has completed over 45% of its 35,300-metre grade control and infill drilling program at the Gold Duke Project, receiving initial assay results from the Eagle prospect. The company is finalizing an updated scoping study and secured $3 million in non-dilutive funding to support a planned mining start in late 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Mont Royal Resources Ltd (ASX – MRZ) has lodged a prospectus to raise between A$8 million and A$10 million through a share offer priced at A$0.20 each, coinciding with a proposed merger with Commerce Resources Corp (TSXV – CCE). The combined entity aims to become a leading Quebec-focused critical minerals developer.